^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    thiotepa

    i
    Other names: DSP-1958
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor, Alkylating agent
    Related drugs:
    3d
    A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant (clinicaltrials.gov)
    P2, N=59, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule)
    |
    TP53 mutation
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan
    4d
    Cord Blood Transplantation in Children and Young Adults With Blood Cancer (clinicaltrials.gov)
    P2, N=71, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial
    |
    TP53 (Tumor protein P53) • KMT2A (Lysine Methyltransferase 2A)
    |
    cyclophosphamide • clofarabine • fludarabine IV • thiotepa • busulfan • cyclosporine
    4d
    COSI: A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT (clinicaltrials.gov)
    P2/3, N=333, Active, not recruiting, University of Birmingham | Trial completion date: Mar 2025 --> May 2026 | Trial primary completion date: Mar 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation) • fludarabine IV • thiotepa • busulfan
    5d
    Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Sawa Ito, MD
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • fludarabine IV • thiotepa • busulfan
    6d
    TBF-AML: TBF Conditioning Regimen for Haploidentical Stem Cell Transplantation in Elderly AML Patients in First Complete Remission (clinicaltrials.gov)
    P=N/A, N=93, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New trial
    |
    fludarabine IV • thiotepa • busulfan
    10d
    Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1, N=33, Recruiting, City of Hope Medical Center | Trial completion date: Jun 2027 --> Mar 2030 | Trial primary completion date: Jun 2027 --> Mar 2030
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    melphalan • fludarabine IV • thiotepa • Orca-T
    17d
    Study on the reduction of cardiac toxicity in children with aplastic anemia undergoing haploidentical hematopoietic stem cell transplantation pretreatment regimen containing Thiotepa Injection (ChiCTR2600120496)
    P=N/A, N=79, Recruiting, Peking University People's Hospital; Peking University People's Hospital
    New trial
    |
    thiotepa
    18d
    Study of Thiotepa Combination With Melphalan (TM Protocol) Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma：A Prospective Randomized Controlled Clinical Trial (clinicaltrials.gov)
    P=N/A, N=204, Not yet recruiting, First Affiliated Hospital Xi'an Jiaotong University
    New trial
    |
    CD34 (CD34 molecule)
    |
    melphalan • thiotepa
    26d
    CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (clinicaltrials.gov)
    P1, N=60, Recruiting, St. Jude Children's Research Hospital | Initiation date: Mar 2026 --> Jun 2026
    Trial initiation date
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    1m
    PRISM: Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma (clinicaltrials.gov)
    P2, N=38, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    temozolomide • thiotepa
    1m
    MBMET_MEYER2017: An interventional, open-label, Phase II study, to evaluate safety and efficacy of standard and high-dose chemotherapy associated with craniospinal irradiation in patients with metastatic medulloblastoma and other embryonal tumours (2024-518964-11-01)
    P1/2, N=18, Active, not recruiting, Azienda Ospedaliera Universitaria Meyer IRCCS | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    carboplatin • cyclophosphamide • etoposide IV • vinorelbine tartrate • lomustine • thiotepa
    2ms
    IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study (clinicaltrials.gov)
    P2, N=31, Completed, Zhejiang Cancer Hospital
    New P2 trial
    |
    ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive
    |
    Rituxan (rituximab) • dexamethasone • thiotepa